Solange Peters, MD-PhD

Solange Peters, MD-PhD, achieved her MD from the Medical School at the University of Lausanne in 1998, following this she attended the Microbiology Institute at the University of Lausanne until 2002, concluding with a MD-PhD thesis on new HIV drug-resistance mechanisms.
From 2002-2006, Prof. Peters did her residency in Internal Medicine, followed by a Fellowship at the Multidisciplinary Oncology Centre, both at the University Hospital of Lausanne. In September 2006, she sat the ESMO Examination in Oncology and was awarded the ESMO Best European Exam result.
Prof. Peters is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan in Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute.
Prof. Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally-advanced NSCLC as well as clinical and translational cancer immunotherapy. Her current research projects as a chair are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy for the treatment of NSCLC, SCLC, thymic malignancies and mesothelioma, denosumab in advanced NSCLC, ALK, RET, EGFR as well HER2 inhibitors. She acts as the local PI of lung trials opened in Lausanne Cancer Centre, focused on phase I, predictive biomarkers and NSCLC immunotherapy. In addition, she is a co-PI of several other trials.
Prof. Solange Peters is an active member of the educational programme within ESMO. Prof. Peters is currently President (2020 – 2022) of the European Society for Medical Oncology (ESMO) and a member of the ESMO Faculty for Lung and Other Thoracic Cancers.
She is in parallel active in IASLC where she also acts as a Board Member. She is a member of AACR (American Association for Cancer Research) and EORTC (European Organisation for Research and Treatment of Cancer).
Of national organisations, Prof. Peters is vice President of SAMO (Swiss Academy for Multidisciplinary Oncology), member of SAKK (Swiss Group for Clinical Cancer Research), FMH (Association of Swiss Physicians) and ASMAC/VSAO (Association of Swiss Interns and Residents) and was the president of FOROME (Association Romande pour la formation continue en oncologie médicale) for 5 years.

M. Patricia Rivera, MD

Dr. Rivera is a Professor of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina (UNC) at Chapel Hill. She joined the faculty at UNC in 1995 and co-founded the first Multidisciplinary Thoracic Oncology Program in the country, a premier program that became the model for multidisciplinary care and defined the vital role pulmonologists play in the care of patients with thoracic malignancies. More recently, she founded the Multidisciplinary Lung Cancer Screening Program at UNC and continues to direct both programs. Her expertise includes screening, diagnosis and staging of lung cancer and management of treatment complications. Medical Director Bronchoscopy and PFT Laboratory.
Dr. Rivera holds several vital leadership roles at UNC and for more than 20 years has served national pulmonary and cancer societies including the American Thoracic Society (ATS, The American College of Chest Physicians (CHEST) and the American Cancer Society National Lung Cancer Round Table through numerous leadership roles and by sharing her time, knowledge and passion to advance the field of Thoracic Oncology.

Raja Flores, M.D.

Steven and Ann Ames Professor of Cardiothoracic Surgery
System Chairman, Department of Thoracic Surgery
Mount Sinai Health System

A common theme throughout my career is developing and identifying prognostic factors within the context of surgical management of lung cancer and mesothelioma, asbestos-related diseases. I have written several sentinel publications focusing on survival, patterns of recurrence and complications, in addition to publications with the Libby Epidemiology Research Program team (LERP). I began my life-long commitment to improving lung cancer patient outcomes via VATS lobectomy (a minimally invasive surgical approach requiring only three small incisions) which has become the gold standard in the surgical treatment of early lung cancer. I changed the surgical management of pleural mesothelioma cancer with a landmark study comparing extrapleural pneumonectomy and pleurectomy/decortication. I am also a part of the Mount Sinai World Trade Center health initiative that sees patients with 9/11 cancers and other chronic conditions. These experiences will enhance my ability to transfer this work from the bench to improved patient care.1-3 with over 250 related publications to date and several under review, my energies and commitment to the plight of lung cancer patients remains paramount.

Rolfo Christian

Christian Rolfo, MD, PhD, MBA is the director of the Thoracic Medical Oncology and the Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He specializes in thoracic oncology, drug development and translational oncology.
Dr. Rolfo is also a professor in the Division of Hematology-Oncology at University of Maryland School of Medicine.
Dr. Rolfo received his medical degree from the National University of Córdoba, Argentina in 1996. He completed his residency at University of Milan, Italy. He has earned certifications from the European Oncology Board and the Spanish and Belgian Board and spent an internship at MD Anderson Cancer Center in Houston. Dr. Rolfo actively works on drug development and resistance in lung cancer and mesothelioma treatment. His focus of research are liquid biopsies (exosomes and ctDNA) and molecular profiling, he is involved in druggable biomarkers research and immunotherapy in thoracic cancer.
Dr. Rolfo is on the educational Committee of the International Association for the Study of Lung Cancer (IASLC), Membership Committee of European Society of Medical Oncology (ESMO) and Educational Chair of the International Society of Liquid Biopsies(ISLB). He is a member of the American Society of Clinical Oncology (ASCO) and other societies.
His special interests include: Thoracic Malignancies Treatment (Lung Cancer, Pleural Mesothelioma and Thymoma), Drug Development, Early Clinical Trials, Molecular Oncology, Immunotherapy, Liquid biopsies.

Professor Tony Mok

BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO

Professor Tony S.K. Mok was trained at the University of Alberta, Canada and he subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career.
Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice. He dedicates his work on precision medicine for lung cancer by also engaging in clinical research on oncogene driven lung cancer and immunotherapy. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO. He also contributes to the development of clinical research infra-structure in China and Asia. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.
Professor Mok has contributed to over 250 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. He is the Past President and Past Treasurer of the International Association for the Study of Lung Cancer (IASLC). He is a member of the Board of Directors for ASCO, AstraZeneca, Aurora Tele-Oncology, Sanomics, Hutchison Chi-Med and St. Stephen’s College & Preparatory School. He is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. His work was recognized by numerous awards including Bonnie Addario Award in 2015, Fellowship of the American Society of Clinical Oncology (FASCO) in 2017, Paul Bunn Jr Scientific Award in 2017, National Science and Technology Progress Award in 2017, CSCO Annual Achievement Award in 2017, ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award and Giant of Cancer Care in 2020. His recent article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017.”